Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lysine-specific demethylase 6B (JMJD3/KDM6B) is a histone demethylase that specifically removes methyl groups from trimethylated lysine 27 on histone H3 (H3K27me3), altering chromatin structure and regulating gene expression. It plays roles in development, inflammation, and cancer, with context-dependent oncogenic or tumor-suppressive functions. Inhibitors like GSK-J1, GSK-J4, and JIB04 are used experimentally to study its epigenetic regulation.
Histone demethylation (specifically H3K27me3)
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lysine-specific demethylase 6B (JMJD3).